Development and evaluation of BioScore: A biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma

Alexander S. Parker, Bradley C. Leibovich, Christine M. Lohse, Yuri Sheinin, Susan M. Kuntz, Jeanette E. Eckel-Passow, Michael L. Blute, Eugene D. Kwon

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

BACKGROUND: The authors previously showed that increased tumor expression levels of B7-H1, survivin, and Ki-67 are independent predictors of poor outcome for patients with clear cell renal cell carcinoma (ccRCC). In the current study, they described the creation of a scoring system based on this panel of biomarkers that can be used in tandem with existing clinicopathologic features and algorithms to improve ccRCC outcome prediction. METHODS: The authors used immunohistochemistry to determine tumor expression levels of B7-H1, survivin, and Ki-67 for 634 consecutive ccRCC patients. A multivariate model verified that each biomarker was independently associated with RCC-specific death after adjusting for the remaining 2. A biomarker-based panel, termed BioScore, was generated to predict the likelihood of RCC-specific death. BioScore was tested for its ability to enhance the performance of several clinicopathologic features and algorithms. RESULTS: Patients with high BioScores were 5 times more likely to die from RCCcompared with patients with low BioScores (hazard ratio, 5.03; 95% confidence interval, 3.82-6.61; P < .001). Multivariate adjustment for individual clinicopathologic features or existing prognostic algorithms failed to attenuate this positive association. Moreover, an examination of concordance indexes revealed that BioScore significantly enhanced the prognostic ability of each of the individual prognostic features or algorithms studied. CONCLUSIONS: The authors described the creation of BioScore, a biomarker-based scoring system that can be used in tandem with established prognostic algorithms to further enhance ccRCC outcome prediction. The need for external validation notwithstanding, they envision that BioScore can be readily updated as new biomarkers are identified.

Original languageEnglish (US)
Pages (from-to)2092-2103
Number of pages12
JournalCancer
Volume115
Issue number10
DOIs
StatePublished - May 15 2009

Fingerprint

Renal Cell Carcinoma
Biomarkers
Neoplasms
Immunohistochemistry
Confidence Intervals

Keywords

  • Biological
  • Carcinoma
  • Kidney neoplasms
  • Renal cell
  • Survival
  • Tumor biomarkers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Parker, A. S., Leibovich, B. C., Lohse, C. M., Sheinin, Y., Kuntz, S. M., Eckel-Passow, J. E., ... Kwon, E. D. (2009). Development and evaluation of BioScore: A biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer, 115(10), 2092-2103. https://doi.org/10.1002/cncr.24263

Development and evaluation of BioScore : A biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. / Parker, Alexander S.; Leibovich, Bradley C.; Lohse, Christine M.; Sheinin, Yuri; Kuntz, Susan M.; Eckel-Passow, Jeanette E.; Blute, Michael L.; Kwon, Eugene D.

In: Cancer, Vol. 115, No. 10, 15.05.2009, p. 2092-2103.

Research output: Contribution to journalArticle

Parker, AS, Leibovich, BC, Lohse, CM, Sheinin, Y, Kuntz, SM, Eckel-Passow, JE, Blute, ML & Kwon, ED 2009, 'Development and evaluation of BioScore: A biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma', Cancer, vol. 115, no. 10, pp. 2092-2103. https://doi.org/10.1002/cncr.24263
Parker AS, Leibovich BC, Lohse CM, Sheinin Y, Kuntz SM, Eckel-Passow JE et al. Development and evaluation of BioScore: A biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer. 2009 May 15;115(10):2092-2103. https://doi.org/10.1002/cncr.24263
Parker, Alexander S. ; Leibovich, Bradley C. ; Lohse, Christine M. ; Sheinin, Yuri ; Kuntz, Susan M. ; Eckel-Passow, Jeanette E. ; Blute, Michael L. ; Kwon, Eugene D. / Development and evaluation of BioScore : A biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. In: Cancer. 2009 ; Vol. 115, No. 10. pp. 2092-2103.
@article{53e491f7be8e43abba37356017010280,
title = "Development and evaluation of BioScore: A biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma",
abstract = "BACKGROUND: The authors previously showed that increased tumor expression levels of B7-H1, survivin, and Ki-67 are independent predictors of poor outcome for patients with clear cell renal cell carcinoma (ccRCC). In the current study, they described the creation of a scoring system based on this panel of biomarkers that can be used in tandem with existing clinicopathologic features and algorithms to improve ccRCC outcome prediction. METHODS: The authors used immunohistochemistry to determine tumor expression levels of B7-H1, survivin, and Ki-67 for 634 consecutive ccRCC patients. A multivariate model verified that each biomarker was independently associated with RCC-specific death after adjusting for the remaining 2. A biomarker-based panel, termed BioScore, was generated to predict the likelihood of RCC-specific death. BioScore was tested for its ability to enhance the performance of several clinicopathologic features and algorithms. RESULTS: Patients with high BioScores were 5 times more likely to die from RCCcompared with patients with low BioScores (hazard ratio, 5.03; 95{\%} confidence interval, 3.82-6.61; P < .001). Multivariate adjustment for individual clinicopathologic features or existing prognostic algorithms failed to attenuate this positive association. Moreover, an examination of concordance indexes revealed that BioScore significantly enhanced the prognostic ability of each of the individual prognostic features or algorithms studied. CONCLUSIONS: The authors described the creation of BioScore, a biomarker-based scoring system that can be used in tandem with established prognostic algorithms to further enhance ccRCC outcome prediction. The need for external validation notwithstanding, they envision that BioScore can be readily updated as new biomarkers are identified.",
keywords = "Biological, Carcinoma, Kidney neoplasms, Renal cell, Survival, Tumor biomarkers",
author = "Parker, {Alexander S.} and Leibovich, {Bradley C.} and Lohse, {Christine M.} and Yuri Sheinin and Kuntz, {Susan M.} and Eckel-Passow, {Jeanette E.} and Blute, {Michael L.} and Kwon, {Eugene D.}",
year = "2009",
month = "5",
day = "15",
doi = "10.1002/cncr.24263",
language = "English (US)",
volume = "115",
pages = "2092--2103",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Development and evaluation of BioScore

T2 - A biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma

AU - Parker, Alexander S.

AU - Leibovich, Bradley C.

AU - Lohse, Christine M.

AU - Sheinin, Yuri

AU - Kuntz, Susan M.

AU - Eckel-Passow, Jeanette E.

AU - Blute, Michael L.

AU - Kwon, Eugene D.

PY - 2009/5/15

Y1 - 2009/5/15

N2 - BACKGROUND: The authors previously showed that increased tumor expression levels of B7-H1, survivin, and Ki-67 are independent predictors of poor outcome for patients with clear cell renal cell carcinoma (ccRCC). In the current study, they described the creation of a scoring system based on this panel of biomarkers that can be used in tandem with existing clinicopathologic features and algorithms to improve ccRCC outcome prediction. METHODS: The authors used immunohistochemistry to determine tumor expression levels of B7-H1, survivin, and Ki-67 for 634 consecutive ccRCC patients. A multivariate model verified that each biomarker was independently associated with RCC-specific death after adjusting for the remaining 2. A biomarker-based panel, termed BioScore, was generated to predict the likelihood of RCC-specific death. BioScore was tested for its ability to enhance the performance of several clinicopathologic features and algorithms. RESULTS: Patients with high BioScores were 5 times more likely to die from RCCcompared with patients with low BioScores (hazard ratio, 5.03; 95% confidence interval, 3.82-6.61; P < .001). Multivariate adjustment for individual clinicopathologic features or existing prognostic algorithms failed to attenuate this positive association. Moreover, an examination of concordance indexes revealed that BioScore significantly enhanced the prognostic ability of each of the individual prognostic features or algorithms studied. CONCLUSIONS: The authors described the creation of BioScore, a biomarker-based scoring system that can be used in tandem with established prognostic algorithms to further enhance ccRCC outcome prediction. The need for external validation notwithstanding, they envision that BioScore can be readily updated as new biomarkers are identified.

AB - BACKGROUND: The authors previously showed that increased tumor expression levels of B7-H1, survivin, and Ki-67 are independent predictors of poor outcome for patients with clear cell renal cell carcinoma (ccRCC). In the current study, they described the creation of a scoring system based on this panel of biomarkers that can be used in tandem with existing clinicopathologic features and algorithms to improve ccRCC outcome prediction. METHODS: The authors used immunohistochemistry to determine tumor expression levels of B7-H1, survivin, and Ki-67 for 634 consecutive ccRCC patients. A multivariate model verified that each biomarker was independently associated with RCC-specific death after adjusting for the remaining 2. A biomarker-based panel, termed BioScore, was generated to predict the likelihood of RCC-specific death. BioScore was tested for its ability to enhance the performance of several clinicopathologic features and algorithms. RESULTS: Patients with high BioScores were 5 times more likely to die from RCCcompared with patients with low BioScores (hazard ratio, 5.03; 95% confidence interval, 3.82-6.61; P < .001). Multivariate adjustment for individual clinicopathologic features or existing prognostic algorithms failed to attenuate this positive association. Moreover, an examination of concordance indexes revealed that BioScore significantly enhanced the prognostic ability of each of the individual prognostic features or algorithms studied. CONCLUSIONS: The authors described the creation of BioScore, a biomarker-based scoring system that can be used in tandem with established prognostic algorithms to further enhance ccRCC outcome prediction. The need for external validation notwithstanding, they envision that BioScore can be readily updated as new biomarkers are identified.

KW - Biological

KW - Carcinoma

KW - Kidney neoplasms

KW - Renal cell

KW - Survival

KW - Tumor biomarkers

UR - http://www.scopus.com/inward/record.url?scp=65649097342&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649097342&partnerID=8YFLogxK

U2 - 10.1002/cncr.24263

DO - 10.1002/cncr.24263

M3 - Article

C2 - 19296514

AN - SCOPUS:65649097342

VL - 115

SP - 2092

EP - 2103

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -